NRx Pharmaceuticals (NASDAQ:NRXP) (NRx), a clinical stage, global biopharmaceutical company, today announced that the Nation of Georgia’s Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous ZYESAMI™ (aviptadil) for the treatment of Critical COVID-19.
NRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
“Lead investigators from our ZYESAMI™ clinical trials are on their way to the Nation of Georgia and will be on the ground there within 24 hours to start teaching physicians how to administer ZYESAMI™ to some of the sickest of COVID patients,” said Prof. Jonathan Javitt, MD, MPH, Chief Executive Officer and Chairman of the Board of NRx. “The repeating ferociousness of this pandemic is of great concern, and we hope ZYESAMI™ can have a real-world impact, comparable to what we saw in our clinical trials.”
The regulatory approval comes as Georgian doctors are seeing significant, daily increases in COVID-19 cases, hospitalized patients, and specifically, patients in hospital intensive care units.
“This latest wave of COVID-19, brought on by the delta variant has medical professionals in Georgia working throughout each day and night trying to keep people breathing,” said Dr. Ivane Chkhaidze, a leading pulmonary physician in Georgia and a member the Association of Georgia Physicians Leadership Team. “We appreciate the Prime Minister and Minister of Health authorizing the use of ZYESAMI™ and offering Georgian physicians a new treatment to help people recover from this devastating virus.”
Dr. Javier Perez-Fernandez, a lead investigator in the Phase 2b/3 clinical trial of intravenous ZYESAMI™ (aviptadil), and critical care pulmonologist in Miami, Florida, is leading the team of physicians traveling to Georgia to train fellow doctors there about administering ZYESAMI™ and the effects of the medicine. The first Georgian physicians trained in administering ZYESAMI™ comprise twenty of the leading critical care physicians in the country.
The first doses of ZYESAMI™ will arrive in the Nation of Georgia within 24 hours, and discussions are underway with the Ministry of Health to provide access to ZYESAMI™ to Georgians suffering with Critical COVID-19.
Post courtesy of NRx